Clene Inc. · NASDAQ:CLNN

Clene — Technical Presentation

9 slides from Clene's technical presentation

  1. Slide 1: Evidence for Target Engagement and Brain Cellular Energy Metabolism Improvements in Parkinson's Disease

    Evidence for Target Engagement and Brain Cellular Energy Metabolism Improvements in Parkinson’s Disease: Results From The Phase 2 REPAIR-PD Clinical Trial With CNM-Au8 Robert Glanzman MD FAAN1, Jimin Ren PhD2, Richard B. Dewey, III MD2, Austin Rynders, RN1, Karen S. Ho, PhD1, Michael T. Hotchkin1, R

  2. Slide 2: CNM-Au8 Effects on Brain Energetic Metabolites

    Phase 2 CNM-Au8 Effects on Brain Energetic Metabolites A Phase 2, Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State (REPAIR) -16 Visit Visit Visit Vi

  3. Slide 3: REPAIR Program | 31P MRS Imaging Modality at 7T

    REPAIR Program | 31P MRS Imaging Modality at 7T PCr Average change in Area Under Curve by individual 31P peak (per 2 cm3 voxel, ~600 Partial Volume Coil Piin voxels per subject; all voxels normalized by ATP PCr) Piex PC a- GPE g- b- PE GPC NAD UDPG Full Volume Coil ATP-𝜶, ATP-𝜷, ATP-𝜸 Piin -…

  4. Slide 4: REPAIR-PD | Baseline Demographics

    REPAIR-PD | Baseline Demographics Baseline Subjects Age Time from MMSE Hoehn & Background Values n [yrs.] Diagnosis [Score] Yahr Stage Dopaminergic (%) mean to BL mean mean Therapy (SD) (SD) (SD) [Months] (%) mean (SD) 13 65.9 17.2 28.8 2.0 All 100% (100%) (7.8) (8.8) (1.3) (0.0) 6 67.0 13.5 28.5 2.

  5. Slide 5: REPAIR Program Primary Endpoint Pre-specified Integrated Analysis (MS & PD Cohorts)

    REPAIR Program Primary Endpoint Pre-specified Integrated Analysis (MS & PD Cohorts) 5

  6. Slide 6: REPAIR-PD | NAD+/NADH Ratio and % Fractions

    REPAIR-PD | NAD+/NADH Ratio and % Fractions Primary Endpoint Data from Parkinson's Disease Cohort 6

  7. Slide 7: REPAIR-PD | β-ATP & Phosphorylation Potential

    REPAIR-PD | β-ATP & Phosphorylation Potential Normalization by Wk12 (% Change vs. BL) 7

  8. Slide 8: Safety Summary

    REPAIR-PD | Safety Summary • Treatment-emergent AEs were mild & transient • No serious adverse events • No subjects with clinically significant laboratory abnormalities • No significant change (i.e., worsening) of UPDRS 8

  9. Slide 9: REPAIR-PD | Results & Conclusions

    REPAIR-PD | Results & Conclusions • Statistically significant increase in NAD/NADH ratio based on integrated analyses of PD & MS cohorts • PD population trend in NAD+/NADH ratio improvement driven by both + increased NAD and decreased NADH • Homeostatic effects on brain energetic metabolites includi

Clene — Technical Presentation on 6ix